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Obese with higher FNDC5/Irisin 
levels have a better metabolic 
profile, lower lipopolysaccharide 
levels and type 2 diabetes risk
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ABSTRACT
Objective: Thus, the aim of this study was to compare if higher or smaller fibronectin type 3 
domain-containing protein 5 (FNDC5)/irisin levels are associated with inflammatory and metabolic 
markers, caloric/macronutrient intake, physical fitness and type 2 diabetes mellitus (T2DM) 
risk in obese middle-aged men, and also to correlate all variables analyzed with FNDC5/irisin. 
Subjects and methods: On the basis of a cluster study, middle-aged obese men (IMC: 31.01 ± 
1.64 kg/m²) were divided into groups of higher and smaller levels of FNDC5/irisin. The levels 
of leptin, resistin, adiponectin, tumor necrosis factor alpha (TNFα), interleukin 6 and 10 (IL6, 
IL10), lipopolysaccharide (LPS), glucose, insulin, glycated hemoglobin, insulin resistance and 
sensibility, lipid profile, risk of T2DM development, body composition, rest energy expenditure, 
caloric/macronutrient intake and physical fitness were measured. Results: The higher FNDC5/
irisin group presented improved insulin sensibility (homeostasis model assessment – sensibility 
(HOMA-S) (p = 0.01) and QUICKI index (p < 0.01)), insulin (p = 0.02) and triglyceride levels 
(p = 0.01), lower insulin resistance (homeostasis model assessment – insulin resistance (HOMA-IR) 
(p = 0.01), triglycerides/glucose (TYG index) (p = 0.02), neck circumference (p = 0.02), risk of T2DM 
development (p = 0.02), tendency to decrease serum resistin (p = 0.08) and significant lower LPS 
levels (p = 0.02). Inverse correlations between FNDC5/irisin and body weight (r -0.46, p = 0.04), neck 
circumference (r -0.51, p = 0.02), free fat mass (r -0.49, p = 0.02), triglycerides (r -0.43, p = 0.05) and risk 
of developing T2DM (r -0.61, p = 0.04) were observed. Conclusions: These results suggest that higher 
FNDC5/irisin levels in obese middle-aged men are related to a better metabolic profile and lower risk 
of T2DM development and serum LPS, a potential inducer of insulin resistance. Arch Endocrinol Metab. 
2017;61(6):524-33
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INTRODUCTION
I risin is a peptide secreted mainly by adipose tissue and muscles after the stimulation of peroxisome 
proliferator activates receptor gamma coactivator 1 
alpha (PGC1alpha) and subsequent secretion and 
cleavage of fibronectin type 3 domain-containing 
protein 5 (FNDC5) by stimulus such as physical 
exercise and exposure to cold (1). In adipose tissue, 
especially in inguinal fat cells, irisin increases the 
expression of mitochondrial uncoupling protein 1 
(UCP1) and, consequently, the energy expenditure and 
consumption of lipid reserves, which could contribute 
to treatment and prevention of metabolic diseases (1). 
Indeed, such irisin effect in inguinal seems to increase 
a special kind of adipocyte cell named brite or beige 
that show characteristics of white (basal) and brown 
adipocytes (after irisin stimulus) (2). Several factors 
are related interfering in FNDC5/irisin levels, as body 
composition, cold exposure, physical exercise, physical 
fitness and leptin levels (3-5).
The optimal levels of circulating FNDC5/irisin in 
humans are not established, however, some evidence 
indicates that individuals with type 2 diabetes mellitus 
(T2DM) (6,7) and metabolic syndrome and insulin 
resistance (IR) (8) have lower levels of this peptide, 
indicating that a larger amount of FNDC5/irisin 
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could be a protective factor against these diseases. 
Paradoxically, some studies have shown that the 
presence of these diseases positively correlates with 
high levels of FNDC/irisin (9-11). Thus, such topic 
is still controversial and need to be further carefully 
investigated. 
It is well known that there is an important imbalance 
in the secretion of cytokines in obese individuals, which 
increases the risk of developing metabolic disorders and 
diseases (12). Cytokines levels associated with clinical 
metabolic markers are strong predictors of the risk of 
developing IR and T2DM (12). Besides cytokines, the 
toll-like receptor 4 (TLR4) stimulus by its main ligand 
lipopolysaccharide (LPS) is also strongly associated 
with IR because TLR4 activation increases tumor 
necrosis factor alpha (TNFα) expression, which in turn 
impairs insulin signaling pathway in several tissues such 
as muscle and adipose tissue (13,14).
Although FNDC5/irisin levels and inflammatory 
markers have been related to glucose metabolism, the 
potential association between these markers is not yet 
established. Moreover, there are doubts whether higher 
or lower FNDC5/irisin levels are related to metabolic 
homeostasis, mainly in individuals with metabolic risk 
due to excess body fat. Based on these aspects, the aim of 
this study was to compare if higher or smaller FNDC5/
irisin levels are associated with inflammatory and 
metabolic markers, along with caloric/macronutrient 
intake, physical fitness and T2DM risk in obese middle-
aged men with the absence of overt disease, through a 
cluster study, and also to correlate all variables analyzed 
with FNDC5/irisin.
SUBJECTS AND METHODS
Subjects
Inactive middle-aged (48,54 ± 5,91 years) male 
individuals, with body mass index (IMC: 31.01 ± 
1.64 kg/m²), were recruited for the study through the 
local media.
Before the men’s inclusion in the study, a complete 
medical examination was carried out, and individuals 
were excluded if they had an acute illness, severe 
hypertension, diabetes mellitus, myocardial infarction 
or orthopedic limitations. They should not be using any 
medication (as anti-diabetic, beta blocker, exogenous 
insulin, anti-inflammatory, thyroid hormone) that 
would interfere with the results. Participants could 
not be involved in regular exercise programs during 
the previous 12 months according to the Baecke 
Habitual Physical Activity Questionnaire and had to 
be insufficiently active according to the International 
Physical Activity Questionnaire (IPAQ) (15).
The individuals who met the criteria, and were 
approved at the initial medical evaluation, were assigned 
to the higher irisin group (HIG) and the smaller irisin 
group (SIG) after the cluster analysis was performed, 
as described in the Statistical analyses section. Twenty-
two individuals matched the inclusion criteria, but two 
of them were excluded for not having all the required 
qualifications. Therefore, twenty individuals completed 
the study, and were divided into HIG (n = 11) and 
SIG (n = 9). The study protocol were explained 
before written consent was obtained. The study was in 
compliance with the Declaration of Helsinki and the 
procedures were previously approved by the Research 
Ethics Committee of the University of Campinas 
(appraisal number n° 1278/2011) and all subjects gave 
written informed consent before taking part.
Experimental design
This is a cross-sectional study using a cluster approach. 
We evaluated cardiorespiratory fitness, muscle strength, 
resting metabolic rate (RMR), anthropometric 
parameters, body composition, feeding behavior, 
measurements of FNDC5/irisin, inflammatory markers 
and total cholesterol (TC), HDL-cholesterol (HDL), 
LDL-cholesterol (LDL), triglycerides (TG), insulin, 
glucose, glycated hemoglobin (HbA1c), homeostatic 
model assessment 2 beta, insulin sensibility and 
resistance (HOMA2B, S, IR), triglycerides and glucose 
index (TYG index), Quick index, systolic and diastolic 
blood pressure and diabetes mellitus type 2 index risk 
(T2DM index risk). 
Anthropometry and body fat 
Body weight was measured with a calibrated manual 
scale (Filizola, São Paulo, Brazil) with a precision of 
0.1 kg. Height was measured with a wall-mounted 
stadiometer, with a precision of 0.1 cm. BMI was 
calculated from the weight and height values. Neck 
(NC) and waist circumference (WC) were measured 
by the commonly established anatomical landmarks. 
Body density was estimated by the skinfold procedure 
with a skin-fold caliper (Lange, Beta Technology, Santa 
Cruz, CA, USA) at the chest, abdomen, thigh, triceps, 
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subscapular, suprailiac, and mid-axillary points. The 
body fat percentage was obtained from body density 
with the Siri equation (16). The subcutaneous and 
visceral abdominal fat thickness was measured by the 
abdominal ultrasound method (17). All assessments 
were performed by the same professional.
Blood sampling
Blood samples (~20 mL) were obtained from the 
antecubital vein in the morning (07.00 to 09.00), after 
12h overnight fasting. All samples were divided into 
aliquots, processed immediately after collection and 
frozen at -80°C until later analysis. Serum samples 
were used for lipid profile and plasma (using EDTA 
antigulant) samples were used for irisin, glucose, insulin 
and HbA1c analysis.
Lipid profile, glucose and insulin
Concentrations of TC, TG, HDL-C, and glucose were 
analyzed with an automatic analyzer (Technicon RA 
1000 Chemistry Analyzer) and a commercially available 
kit (Laborlab, São Paulo, Brazil). The LDL-C was 
calculated according to the Friedewald equation (18). 
The insulin was determined by chemiluminescence with 
commercial kits (Elecsys insulin kit, Roche Diagnostics 
GmbH, Indianapolis, IN, USA) and an automatic 
biochemical analyzer (ARCHITECT i2000 SR, Abbot 
Diagnostics, IL, USA). The HbA1c was verified by 
high pressure liquid chromatography high performance 
(HPLC).
FNDC5/irisin and adipokine measurements
FNDC5/irisin values were determined, duplicated 
by enzyme-linked immunosorbent assay (ELISA), 
according to the specifications of the manufacturer 
(Quantikine High-Sensitivity Kit (Lot n° L13112659), 
United States Biological, Swampscott, MA, USA). This 
is a polyclonal antibody kit, with capacity to identify 
FNDC5 complete protein and cleaved FNDC5 (Irisin). 
The kit also has the not cross-react with human peptides 
that have molecular patterns similar to FNDC5/Irisin 
as: fibronectin type III domain containing 4 (FNDC4), 
adiponectin, nicotinamide phosphoribosyltransferase 
(Nampt), retinol-binding protein 4 (RBP4), clusterin, 
leptin, vaspin, glutathione peroxidase 3 (GPX3), 
resistin, angiotensin-converting enzyme 2 (ACE2), 
lipocalin-2, angiopoietin-like protein3 (ANGPTL3), 
angiopoietin-like protein3 (ANGPTL6), delta and 
notch-like epidermal growth factor-related receptor 
(DNER), delta homolog 1 (DLK1), calreticulin and 
interleukin 33. The values are presented in micrograms 
per milliliter (ug/mL). The sample sensitivity was 1 
nanogram per milliliter (ng/ml). The test range was 
0.001-5 ug/ml. The values of all subjects, regardless 
of the group, are within range. The intra-assay and 
inter-assay kit coefficient and sensitivity were as follows: 
4.86%, 8.02% and 1 ng/mL. All samples were measured 
in the same plates and collect in the same period. 
Serum concentrations of resistin, leptin and 
adiponectin, TNF-α, interlukin 6 and interleukin 10 
(IL6; IL10) were also determined by ELISA, following 
the specifications of the manufacturer (Quantikine 
High-Sensitivity Kit, R&D Systems, Minneapolis, 
MN, USA). The intra- and interassay coefficients and 
the sensitivity were as follows: TNF-α; 3.8%, 6.0% 
and 0.010 ng/mL; 7.4%, 6.5%, and 0.039 pg/mL for 
IL-6; 4.6%,7.8%, and 0.09 pg/mL for IL-10; 3.0%, 
3.5% and 7.8 pg/mL for leptin; 2.8%, 5.9% and 0.246 
ng/ml for adiponectin; 3.8%, 7.8% and 0.026 ng/mL 
for resistin.
To analyze LPS levels, plasma samples were diluted 
to 20% with endotoxin-free water and then heated to 
70°C for 10 min to inactivate plasma proteins. Then 
serum LPS was quantified with a commercially available 
Limulus Amebocyte assay from Cambrex (Walkersville, 
MD, USA) according to the manufacturer’s protocol. 
The samples were duplicated and the background 
subtracted.
Blood pressure
Systolic and diastolic blood pressure assessments were 
performed after approximately 10 minutes of rest with 
a mercury sphygmomanometer and a stethoscope. The 
measurements were taken in the supine position by the 
same professional. All measurements were duplicated 
and the average of the two assessments was used. 
Formulas/Indexes
Beta-cell function, insulin sensibility and resistance 
were calculated respectively by the HOMA calculator 
using fasting concentrations of glucose and insulin 
equation (19).
Insulin resistance was also verified by the TYG 
index using the equation (fasting triglycerides 
(mg/dL) x fasting glucose (mg/dL)/2) (20). Insulin 
sensibility was evaluated using the QUICKI index by 
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the following equation: Quicki = 1 ÷ (Log insulin + 
Log glicose) (21). 
The risk of T2DM development was calculated with 
the algorithm for prediction of this disease in middle-
aged adults in the Framingham Offspring study (22). 
Maximal-strength assessments
Maximal strength was measured by a one maximum 
repetition test (1RM) on bench press, leg press and 
arm curl exercises, performed on NakaGym equipment 
(São Paulo, Brazil). The 1RM tests were conducted as 
in Libardi and cols. (23). Before the beginning of the 
study, individuals performed two familiarization trials 
interleaved with 48h periods, to reduce the learning 
effects, as well as to establish the reproducibility of the 
tests in the exercise.
Cardiorespiratory fitness test
The individuals performed a maximum-effort protocol 
on a Quinton TM55 treadmill (Bothell, WA, USA), 
where gas exchange data was collected continuously 
by means of an automated breath-by-breath metabolic 
cart (CPX; Medical Graphics, St Paul, MN, USA) (23).
Rest metabolic rate (RMR)
The RMR was determined from oxygen consumption 
(O2) and carbon dioxide production (CO2) by indirect 
calorimetry of open circuit by the gas analysis system 
(CPX Ultima, MedGraphics, USA) and calculated in 
daily values (kcal/day) by the Weir equation (24).
The test was performed under laboratory conditions 
and after a fasting period of 12 hours. Volunteers used 
the gas analyzer connected to a facial mask, remaining 
silent in the supine position, avoiding movement and 
sleeping for 30 min (the initial 10 min were discarded), 
so that breath after breath could be obtained. The gas 
analyzer was calibrated before each test. 
Evaluation of caloric and macronutrient intake
Volunteers received diet records (DR) from trained 
nutritionists, who explained individually how to 
complete these records. Food scales were distributed 
and individuals were requested to list all food ingested 
during three-day food records to register intake on three 
different and non-consecutive days (two weekdays and 
one weekend day). 
After completing the DR, the team of nutritionists 
met the volunteers so that if the data were not 
satisfactory consumer information could be compiled 
accurately. DRs were analyzed by Dietpro version 5i 
software. The estimation of nutrient intake was made 
with based in TACO/Unicamp table and USDA. The 
food intake assessment was derived from the average 
data of three recalls (25).
Statistical analysis
Initially, using cluster analysis was performed (K-means 
cluster) with Statistica 6 software (StatSoft, USA) 
using the FNDC5/irisin level of each subject. This is 
an exploratory multi-variance analysis technique that 
allows classifying a set of data into homogeneous groups 
through similarities or dissimilarities between them. By 
“k means cluster” is possible to include the number of 
groups according to convenience. In function on the 
number of subjects we established two groups (higher 
and smaller irisin). After the establishment of the number 
of groups, the system assigned a centroid to each group. 
Subsequently each data (numerical object of the data 
set) has its Euclidean distance calculated with these 
centroids by means of a distance measure. The criterion 
for a data/numerical object to be allocated in a given 
group is its shortest distance from the centroid. After the 
cluster group’s definition, data distribution was tested 
by the Shapiro–Wilk test. A Student’s t-test was applied 
to analyze differences between clusters for parametric 
distributed variables and the Mann-Whitney U-test was 
used to compare the non-parametric distributed variables. 
We performed also correlations, using the Pearson’s 
correlation between FNDC5/irisin for the parametric 
distributed variables and the Spearman’s rank correlation 
to FNDC5/irisin for non-parametric distributed variables. 
Parametric distributed variables were expressed as mean 
± standard deviation while non-parametric variables were 
expressed as median (Interquartile range). The p-value 
significance level was P ≤ 0.05 for all analyses.
RESULTS
Table 1 presents anthropometric, body composition, 
caloric/macronutrient intake, physical fitness and RMR 
values of Higher Irisin Group (HIG) and Smaller Irisin 
Group (SIG). The hallmark results were that HIG had 
smaller weight (p = 0.04), neck circumference (p = 
0.02) and lipid intake (p = 0.05).
Table 2 shows the glycemic homeostasis markers, 
lipid profile and systolic/diastolic blood pressure values 
of both groups. HIG compared to SIG presented 
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Table 1. Anthropometric markers, body fat, caloric/macronutrient intake, physical fitness and rest metabolic rate of groups higher and smaller irisin
Variable Higher Irisin  Group (HIG) n = 11
Smaller Irisin  
Group (SIG) n = 9
Age (years) 49.09 (45.33-52.84) 48 (43.20-52.80)
Weight (kg) 90.16 ± 6.66 96.68 ± 7.02*
Height (m) 1.72 ± 0.06 1.75 ± 0.05
BMI (kg/m2) 30.63 ± 1.68 31.47 ± 1.57
Body fat (%) 35.47 ± 5.43 34.05 ± 4.59
Waist circumference (cm) 101.1 ± 5.2 102.7 ± 4.7
Neck circumference (cm) 40.88 ± 1.56 42.87 ± 1.99*
US SF (mm) 26.1 ± 8.7 24.76 ± 6.10
US VF (mm) 65.46 ± 14.33 68.32 ± 19.43
Carbohydrates (g/day) 257 ± 56 276 ± 90
Lipids (g/day) 76.10 ± 22 100.59 ± 32*
Proteins (g/day) 99.5 ± 6 107.8 ± 27.5
Caloric Intake (kcal) 2154 ± 471 2515 ± 695
1 RM leg press (kg) 293 ± 84.88 302 ± 56.4
1RM bench press (kg) 70.5 ± 15.79 70.14 ± 15.81
1RM arm curl (kg) 29.18 (26.16-32.19) 30.57 (26.62-34.51)
VO2max. (mL/kg-1/min-1) 26.84 ± 3.64 25.95 ± 4.04
RMR (kcal) 1331 ± 200.82 1397 ± 235.52
BMI: body mass index; US SF: ultrasound subcutaneous fat; US VF: ultrasound visceral fat; RM: maximum repetition; VO
2
max.: maximum volume of oxygen; RMR: Rest metabolic rate. *: Significant difference 
HIG and SIG (p < 0.05). Parametric variables were expressed as the mean ± standard deviation; non-parametric variables were expressed as the median (Interquartile range).
Table 2. Biochemical, metabolic indexes and hemodynamic markers of groups higher and smaller Irisin
Variable Higher Irisin Group (HIG) n = 11
Smaller Irisin 
Group (SIG) n = 9
Fasting insulin (uU/mL) 9.14 ± 2.09 14.26 ± 5.9*
Fasting glucose (mmol/l) 5.18 ± 0.25 5.24 ± 0.72
Hb
A1c
 (%) 5.34 (5.15-5.53) 5.35 (4.79-5.91)
HOMA2-B 107.03 (90.93-123.13) 143.03 (87.66-198.39)
HOMA2-S 83.48 ± 23.7 58.16 ± 19.24*
HOMA2-IR 1.23 ± 0.27 1.81 ± 0.71*
QUICKI Index 0.34 ± 0.02 0.31 ± 0.01*
TYG Index 4.69 ± 0.19 4.87 ± 0.21*
Triglycerides (mmol/l) 1.43 9 (1.09-1.81) 2.27 (1.60-2.94)*
Total Cholesterol (mmol/l) 4.64 ± 0.90 5.22 ± 1.15
HDL (mmol/l) 1.05 ± (0.94-1.59) 1.09 (0.87-1.31)
VLDL (mmol/l) 0.72 ± 0.33 1.04 ± 0.40†
LDL (mmol/l) 2.86 ± 0.76 3.02 ± 1.04
Systolic pressure (mm/Hg) 125.82 ± 16.26 117.14 ± 12.44
Diastolic pressure (mm/Hg) 87.09 ± 11.95 80.28 ± 5.6
Hb
A1c
: glycated hemoglobin; HOMA-B: homeostatic model assessment – beta; HOMA-S: homeostatic model assessment – sensibility; HOMA-IR: homeostatic model assessment – insulin resistance; 
TYG Index: triglycerides/glucose index; HDL: high density lipoprotein; VLDL: very low density lipoprotein; LDL: low density lipoprotein. *: significant difference between HIG and SIG (p < 0.05). †: trend 
difference between HIG and SIG (p between 0.051 and 0.090). Parametric variables were expressed as the mean ± standard deviation; non-parametric variables were expressed as the median 
(interquartile range).
smaller insulin (p = 0.02), triglyceride levels (p = 0.01), 
and insulin resistance by the HOMA-IR (p = 0.01), 
along with TYG index (p = 0.02). HIG still had better 
insulin sensibility according to HOMA-S (p = 0.01) and 
QUICKI index (p < 0.01). There was also a tendency 
of HIG to exhibit smaller VLDL levels (p = 0.07).
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The FNDC5/irisin, LPS, cytokines and adipokine 
levels are presented in Figure 1 A-H. Besides higher 
FNDC5/irisin levels in HIG (HIG 4.46 ± 0.10 x 
SIG 4.07 ± 0.14, p < 0.01), this group exhibited 
smaller LPS levels (HIG 0.50 ± 0.05 x SIG 0.56 
± 0.06, p = 0.02) and tendency to lower levels of 
resistin (HIG 14.88 ± 8.21 x SIG 23.65 ± 12.93, 
p = 0.08). 
Proving the better metabolic status in HIG, this group 
still showed a smaller risk of developing T2DM (HIG 
4.55 ± 3.01 x SIG 10.88 ± 9.82, p = 0.02) (Figure 2).
About the correlations, there are significant inverse 
correlations between FNDC5/irisin and body weight 
(r -0.46, p = 0.04), neck circumference (r -0.51, p = 
0.02), free fat mass (r -0.49, p = 0.02), triglycerides (r -0.43, 
p = 0.05) and risk of developing T2DM (r -0.61, p = 0.04). 
Figure 1. FNDC5/irisin levels and inflammatory markers of groups higher and smaller irisin. 
HIG and SIG levels of A: FNDC5/irisin. B: LPS (lipopolysaccharide). C: TNF alpha (tumor necrosis factor alpha). D: IL6 (interleukin 6). E: IL10 (interleukin 10). 
F: leptin. G: Resistin. H: adiponectin. *: significant difference between HIG and SIG (p < 0.05). †: Trend difference between HIG and SIG (p between 0.051 
and 0.09).
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DISCUSSION
Herein, using a cluster study, our results show that 
obese middle-aged men with higher irisin levels have a 
better metabolic profile along with lower risk of T2DM 
development and LPS levels. Furthermore some 
anthropometrics/body composition variables and risk 
of T2DM are inversely related to FNDC5/irisin levels.
Interestingly, the better clinical parameters observed 
were associated with high irisin levels, differently of 
other studies that associated lower FNDC5/irisin levels 
to healthy state (9-11). Our results also go against works 
that put in doubt the FNDC5/irisin beneficial effects 
(26). Thus, the present study corroborate clinically 
with early studies in animals and in vitro (1,2) that 
associated FNDC5/irisin stimulus with a metabolic 
improvement in humans. 
The FNDC5/irisin levels have been reason of 
several questionings and doubts. Initially higher serum 
levels were associated with a possible FNDC5/irisin 
resistance, as occur with insulin (11), however our 
results showed that this fact did not occur because 
the HIG showed smaller insulin resistance. Some 
authors have suggested a possible “irisinemia” as 
a compensatory effect of organism to try maintain 
the metabolic homeostasis by irisin secretion (27). 
However, the better hypothesis must be the negative 
influence of hyperglycemia and serum lipids on 
FNDC5/irisin levels, since free fatty acid and glucose 
in vitro stimulation decrease expression/secretion of 
these peptides (28). Our metabolic results associated 
a cluster of FNDC5/irisin levels bring similar clinical 
evidence of this in-vitro study, and consolidate the 
studies that observed lower levels of FNDC5/irisin 
correlated with dysfunctions and metabolic diseases 
(6,8,29,30).
Studies that analyzed the relation of inflammatory 
markers and FNDC5/irisin levels are scarce in the 
literature and the present work show for the first time 
evidences about this context. Given the metabolic 
profile results, it would be expected that HIG exhibited 
better levels of global inflammatory markers, but this is 
partially evidenced through results observed for LPS 
and the trend towards reduction of circulating resistin 
(p = 0.08).
LPS is an endotoxin related to insulin resistance, once 
it binds TLR4 and triggers intracellular inflammatory 
responses (14). The exact relation of FNDC5/irisin 
and LPS levels is something that needs to be better 
understood, however, some hypotheses may be raised, 
such as the LPS interfering negatively on FNDC5/
irisin secretion as observed in other study when glucose 
and free fat acid stimulus in vitro down-regulation 
FNDC5/irisin secretion. On the other hand, FNDC5/
irisin has been associated with endothelial integrity 
(31), and vascular disease and injury can influence LPS 
gut permeability and systemic inflammation (32). 
Interestingly, a recent study showed that LPS 
is a negative regulator of adipose tissue browning 
process (33). However, this work not analyzed the 
relation between LPS and FNDC5/irisin (33). Our 
present results seem to indicate that this negative LPS 
influence in browning process could also involve a 
decrease of FNDC5/irisin, one of the main stimulator 
of these process. Reinforce this idea the higher fat 
intake in SIG because the increase of fat, specially 
the saturated type, is related to LPS absorption, thus 
the LPS increase could be an inhibitor of FNDC5/
irisin, as observed by excess of glucose and free fat 
acids (28), which could explain the LPS as a negative 
regulator of browning (33). Previous study found a 
positive correlation between FNDC5/irisin levels and 
carbohydrate intake (34), indicated, together with our 
result that FNDC5/irisin and macronutrients might 
have an important interaction that certainly needs to 
be deeply addressed in future researches, as well as 
better analyze the relationship between FNDC5/irisin 
and LPS.
The tendency of lower resistin level is another 
positive HIG result, because the increase in this 
adipokine is related to the insulin resistance and worse 
inflammatory condition (12). Also, it is not possible to 
explain the exact relation between FNDC5/irisin and 
resistin levels. New studies could be to focus also on 
these markers relations.
Figure 2. Diabetes mellitus type 2 index risk of groups higher and smaller 
Irisin. 
T2DM: diabetes mellitus type 2. * Significant difference between HIG and 
SIG (p < 0.05).
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Even for adipokine results, although leptin could be 
a negative regulator of FNDC5/irisin (3), our results 
demonstrate that, at least in serum obese men, an inter-
relationship between these biomarkers does not seem 
to occur. Similar to leptin, TNFα, adiponectin, IL 6 
and IL 10 serum are not related to higher or smaller 
FNDC5/irisin levels. However, molecular relationships 
need to be further investigated. 
All of the actions assigned to FNDC5/irisin seems 
to stimulate the increase of lipid substrate consumption 
by mitochondria (1). Based in the FNDC5/irisin effects 
on energy expenditure increase observed in animals and 
in vitro studies (1,2), and also in the better metabolic 
profile verified in HIG, we could expect a difference in 
RMR between HIG and SIG. However, our results did 
not show any significant difference in the RMR between 
two clusters groups. Indeed, such result is in line with 
previous studies (35,36), which also not observed 
the relation between FNDC5/irisin levels and rest 
energy expenditure in humans. The methodology for 
evaluating the rest energy expenditure in the current 
study has been validated previously (24), but it is a 
mix of direct and indirect tests, and perhaps the use of 
only direct methods or tests to evaluate the percentage 
of energy substrates used during rest would results in 
significant difference between groups, because several 
factors can interfere in that variable.
The significant lowest levels of triglycerides and 
downtrend in VLDL in HIG observed in the present 
study corroborate with other study (30), which 
observed that higher levels of lipids in blood and liver 
have correlation with lower FNDC5/irisin levels. 
About correlations, were observed inverse 
associations between FNDC5/irisin and body weight, 
free fat mass, neck circumference, triglycerides and risk 
of developing T2DM risk results, strengthening the 
others find of present work. The body weight, free fat 
mass and triglycerides have been related to FNDC/
irisin (5,30,37), indicating that body composition, 
especially body fat, and serum lipids could has influence 
about levels of this peptides, however, it is important 
to mention that these correlations presented a fragile 
“r” values. Although several metabolic glycemic 
control variables has been associated to FNDC5/
irisin levels, to our knowledge, it is the first time that 
neck circumference (a practice factor related to insulin 
resistance) (38) and a developing risk T2DM global 
index are inversely related to FNDC5/irisin levels, 
indicating, once again, that in humans, the levels of this 
peptides is fully combined with insulin resistance and 
glucose tolerance, as observed in animals and in vitro 
studies (1,39). Based on insulin sensibility and resistance 
observed between groups it would be expected that 
correlation with others markers of glucose homeostasis 
were observed besides neck circumference, however, it 
is important to cite that there are trend statistic between 
FNDC5/irisin and HOMA-S (p = 0.07), Quicki index 
(p = 0.08) and TYG index (p = 0.07), what indicate 
that results go in this direction, perhaps in a higher 
sample of subjects these results could be significant.
The HIG showed higher body weight, however this 
result should not be an intervening factor in the results, 
because both cluster groups have similar BMI, fat mass, 
and waist circumference, parameters that can interfere 
more significantly in FNDC5/irisin levels than body 
weight analyzed in isolation (5). Moreover, the difference 
between the body weight of the groups may be related to 
the average height difference among them (HIG 1.72 m 
x SIG 1.75 m) and BMI similarity between groups prove 
this idea, being this analyze more applicable because the 
weight must be related to the height.
FNDC5/irisin levels difference average between 
HIG and SIG is approximately 10%. Two points can 
support this difference as relevant. First, the difference 
between fasting glucose levels of diabetic subject (126 
mg/dL) and the normoglycemia (99 mg/dL) is around 
20%. Second, a previous study has demonstrated a 
difference about 30% in irisin levels, when comparing 
type 2 diabetic and health subjects (7). Together, these 
data strongly support the idea that in non-diabetic 
people, i.e., insulin resistant people, such 10% difference 
in irisin levels is really significant.
Physical exercise and temperature was reported 
having influence on FNDC5/irisin levels (39). 
However, these factors should not have interfered 
in present results, once both groups underwent the 
experiment during similar periods; the region where the 
research was conducted did not present large thermal 
fluctuations or seasons with extreme temperatures; all 
subjects were not engage in regular exercise programs 
during the previous 12 months and were classified as 
insufficiently active according to the Baecke Habitual 
Physical Activity Questionnaire and International 
Physical Activity Questionnaire (IPAQ) (15). 
The present work is a cross-sectional study, with 
a relatively limited sample size of obese individuals, 
and did not investigate the relationship of cause and 
effect for the results found. However, it is important 
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
532
Metabolic profile, LPS and FNDC5/irisin
Arch Endocrinol Metab. 2017;61/6
to emphasize that these group analyzed is extremely 
homogeneous and were selected by strict inclusion 
criteria. Moreover, the present study analyzed more 
than 40 clinical variables, to our knowledge, are scarce 
in literature human’s studies with FNDC5/irisn and 
these significant numbers of variables investigated. 
Even with a small sample, the evidence here presented 
confirms the FNDC5/irisin positive relation with 
metabolic homeostasis in humans, particularly in obese 
men. Based in the relation of smaller FNDC5/irisin 
with worse metabolic state, these peptides may, in 
the future, be a marker for the presence of metabolic 
diseases and also a therapeutic target. However, the 
ideal FNDC5/irisin values are not known, so further 
work should focus on this aim.
In conclusion, higher FNDC5/irisin levels in grade 
1 obese men are related to a better metabolic profile, 
less risk of developing T2DM, decrease of serum LPS. 
Epidemiological studies with a largest number of 
subjects must be performed to confirm the present 
results and to establish cut-off points for optimal 
FNDC5/irisin levels and also for this peptide to be used 
as a metabolic risk marker. To evaluate a possible and 
exact relationship between FNDC5írisin and LPS, other 
works should also be designed. Lastly, how physical 
exercise are one of the main stimulators of FNDC5/
irisin secretion, studies comparing the exercise effects 
on these peptides level in groups of high and small irisin 
levels also must be considered.
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